View
About the views

Guided View. New to dividends? Yields, ex-dividend dates, payout ratios, DRIP: we explain every term as you browse, in plain English. Same data, with the help built in.

Expert View. You already know the market. Just the data: clean, fast and compact, with no extra explanations. This is the default view.

Theme
Dividendly Independent dividend research

← Back to declarations

LABFF Laboratorios Farmaceuticos Rovi, S.A. — dividend yield, history & ex-dividend dates

Other OTC· Annual dividend· Common Stock · Healthcare / Drug Manufacturers - Specialty & Generic

$67.17 ▲ $0.00(0.00%) as of Oct 29, 2026 06:20 UTC
Sponsored Advanced charts & data →

Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical firm actively involved in the discovery, creation, manufacturing, and commercialization of medicinal products. Its market presence extends across Spain, the European Union, OECD nations, and other international territories. Beyond its proprietary portfolio, Rovi also distributes pharmaceutical offerings under license from other companies. Rovi's diverse product lineup addresses several critical health conditions. Key offerings include Hibor and Becat (an Enoxaparin biosimilar), both low-molecular-weight heparins employed in preventing and managing venous thromboembolic disorders. Neparvis targets symptomatic chronic heart failure with reduced ejection fraction in adults. For hypercholesterolemia, the company offers Absorcol, Vytorin, and Orvatez. Respiratory ailments like chronic obstructive pulmonary diseases (COPD) are treated with long-acting bronchodilators such as Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is prescribed for men experiencing moderate to severe storage and voiding symptoms due to benign prostatic hyperplasia (BPH) who have not responded sufficiently to single-drug therapies. Additionally, Medikinet and Medicebrán provide treatment for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent populations. The firm also supplies a range of specialized hospital products for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventional procedures, Multihance and Prohance for MRI, and Sonovue for ultrasound examinations. Furthermore, Rovi provides advanced contrast injection systems, including EmpowerCTA+, EmpowerMR, and CT Exprès, along with their associated disposable components. Its portfolio extends to over-the-counter (OTC) pharmaceutical products. Moreover, Rovi offers contract development and manufacturing organization (CDMO) services to external businesses, producing pharmaceuticals in diverse forms such as prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi caters to a broad spectrum of healthcare stakeholders, encompassing wholesalers, physicians, nurses, pharmacists, and directly, patients. A notable partnership exists with Moderna, Inc., where Rovi is involved in the manufacturing of mRNA COVID-19 vaccine candidates. Established in 1946 and headquartered in Madrid, Spain,

Dividend Snapshot

StatusGrowing
Last Dividend$1.0963Paid Jul 15, 2026
Forward Annual$1.10From the $1.0963 dividend declared Feb 25, 2026
FrequencyAnnual
Last Ex-DateJul 14, 2026The most recent ex-dividend date that has already passed.
1-Yr Growth-9.0%Annual totals, 2024–2025

Research Scores

Scores describe this security's published financial data on a 0–100 scale using the formulas on our methodology pages. They are the same for every reader, are not a probability or a forecast, and are not a recommendation. Past dividend growth does not guarantee future increases. Report a data error.

Dividend Safety Score

90/100

Very strong indicators

Complete data

Dividend Growth Score

55/100

Moderate growth record

Complete data

Dividend Value Score

Not Rated

only 40% of the inputs available (60% needed)

DividendRank

67/100

Upper middle of the scale

Partial data

How the Dividend Safety Score is built for LABFF
InputValuePointsWeight
Earnings payout ratioEarnings payout ratio 26% (TTM to Jun 30, 2026) 100 20%
FCF payout ratioFCF payout ratio 27% (TTM to Jun 30, 2026) 100 25%
Net debt / EBITDANet cash (TTM to Jun 30, 2026) 100 15%
Interest coverageInterest coverage 56.2x (TTM to Jun 30, 2026) 100 10%
Dividend record9 years of uninterrupted regular payments; last cut Jul 2, 2019 (-35.9%), within 10 years: capped at 50 50 20%
Earnings stabilityNet income positive in 5 of the last 5 fiscal years (FY2021–FY2025) 100 10%

Inputs that are not available are left out and the remaining weights are scaled up. Profile: ordinary company. Formula version 2026-10-19.4.

How the Dividend Growth Score is built for LABFF
InputValuePointsWeight
5-year dividend growth5-year dividend CAGR 45.2% (2020–2025) 100 25%
Consecutive annual increases0 consecutive annual increases (through 2025) 10 20%
Payout headroomHeadroom from the earnings payout ratio 26% (TTM to Jun 30, 2026) 100 20%
Earnings per share growth (3 years)EPS CAGR -9.7% (FY2022–FY2025) 1 15%
Revenue growth (3 years)Revenue CAGR -3.1% (FY2022–FY2025) 21 10%
10-year dividend growthN/A (not used) N/A 10%

Inputs that are not available are left out and the remaining weights are scaled up. Profile: ordinary company. Formula version 2026-10-19.4.

Key Metrics

Current Yield

1.63%

At the Oct 29, 2026 price

The annual dividend as a percentage of the share price. A 3% yield is about $3 of dividends a year for every $100 invested at today's price.

Annualized Dividend

$1.0963

Declared Feb 25, 2026

The latest declared regular dividend scaled to a full year by how often it's paid (for semi-annual payers, the latest two payments), adjusted for stock splits. A $0.25 quarterly dividend annualizes to $1.00. Special dividends are excluded.

Frequency

A Annual

How often the dividend is paid, read from the dates of recent payments: Q = quarterly (4x a year), M = monthly, S = semi-annual, A = annual.

RSI (14)

0

As of Oct 29, 2026

Relative Strength Index (0-100), a price-momentum gauge. Above 70 is often called 'overbought', below 30 'oversold'. A technical signal, not a dividend metric.

52-Week Range

$67.17 – $90.61

Closes through Oct 22, 2026

The lowest and highest price over the past year, showing where today's price sits in its recent range.

Payout Ratio (TTM)

25.83%

12 months to Jun 30, 2026 (Q2 FY2026)

The share of earnings paid out as dividends over the trailing twelve months (TTM): dividends paid divided by net income across the company's four most recent reported quarters, dated by the latest quarter end. A fiscal-year tag such as FY2025 means only annual figures were available. Lower leaves more cushion; above 100% means paying out more than the company earned. It shows n/a for funds and when net income over the period was negative; for REITs and BDCs it is marked EPS-based, since they are judged on FFO/AFFO or net investment income instead.

Years Paying

9

How many years of payments we have on record. This can understate very long histories where our data doesn't reach far enough back.

Price / Book (TTM)

4.39

Price as of Oct 25, 2026; latest reported book value

Price-to-book ratio: the share price on the date shown divided by the latest reported book value per share. A rough valuation gauge, most useful for asset-heavy sectors like REITs, banks and insurers.

S.A.F.E. Dividend Read

S.A.F.E. is a set of four checks on a dividend's record and the company's data, the same test used across the screener and our ranked lists. Solid: a Dividend Safety Score of 70+ and a yield of 2%+. Accelerating: at least three consecutive completed calendar years of higher total regular dividends. Flawless: since 1990, no calendar year whose total regular dividend fell more than 20% below the year before, and no suspension. Enduring: at least 20 years between the first and latest dividend in our records. All four met earns the S.A.F.E. flag.
S Solid
Below the Solid check (Dividend Safety Score 70+ and yield 2%+): Dividend Safety Score 90/100, yield 1.63%.
A Accelerating
Dividend growth has stalled — 0 consecutive annual increase(s), under the 3 this check looks for.
F Flawless
A calendar year's regular dividend total fell more than 20% below the year before.
E Enduring
9 year(s) of payments on record, under the 20 this check looks for.

Quote & Key Data

ExchangeOther OTCThe stock exchange where the shares trade, such as NYSE or Nasdaq.
Volume100Oct 22, 2026 sessionHow many shares changed hands in the trading session dated beside this figure, a rough read on trading activity. Daily bars are refreshed on a slower cycle than the quoted price, so this session can be older than the price above.
Open$67.17Oct 22, 2026 sessionThe price at the start of the trading session dated beside this figure, which can be earlier than the session the quoted price comes from.
Day Range$67.17 – $67.17Oct 22, 2026 sessionThe lowest and highest price during the trading session dated beside this figure, which can be earlier than the session the quoted price comes from.
Prev Close$67.17Close of Oct 21, 2026The closing price from the session before the one dated beside these figures.
Market Cap$3.44BAs of Oct 29, 2026The company's total market value (share price times shares outstanding) on the date shown.
Shares Out51.14MImplied by market cap, Oct 29, 2026Shares outstanding implied by the market cap and share price on the date shown.
EPS (TTM)EUR 3.6212 months to Jun 30, 2026 (Q2 FY2026); reported in EUREarnings per share over the trailing twelve months (TTM), labeled with the end date of the latest reported quarter and shown in the company's reporting currency. Dividends are paid out of these earnings.
P/E (TTM)16.6Price as of Oct 25, 2026; earnings to Jun 30, 2026Price-to-earnings ratio: the share price on the date shown divided by trailing-twelve-month earnings per share. A rough gauge of how richly the stock is valued.
Last Ex-DateJul 14, 2026Paid Jul 15, 2026The most recent ex-dividend date that has already passed.
Next Ex-DateN/ANone declared yetThe ex-dividend date of the next payment the company has declared, or that is scheduled when no declaration is on file. Future dates our data provider only projects are not shown.

Dividend Growth

3-Yr Growth (CAGR)3.5%Annual totals, 2022–2025The dividend's average annual growth rate over the period, compounded.
5-Yr Growth (CAGR)45.2%Annual totals, 2020–2025The dividend's average annual growth rate over the period, compounded.
Consecutive Increases0 yrsAnnual totals through 2025The number of consecutive years the dividend has increased.

Why the Yield Moved (90 Days)

LABFF's dividend yield rose from 1.21% to 1.63% over the past ~90 days (+0.42 pp). Of that move, +0.00 pp came from changes in the dividend rate and +0.42 pp from the share price ($90.61 on Jul 31, 2026 → $67.17 on Oct 29, 2026). A yield that rises because the price fell is not an improvement in the payout itself.

Yield vs Its Own History

Current1.63%
1-Yr Average1.30%
Low / High1.20% – 1.63%
Percentile79%

Across 272 daily observations over the past 13 months (through Oct 22, 2026), LABFF's current yield is higher than approximately 79% of them. Our stored price history for LABFF covers the past 13 months; 3- and 5-year averages are not yet computable from it and are deliberately not shown.

Adjusted Price History

Dividend History

Dividend Payment History

Ex-dividend calendar →
Amount Type Declared Ex-Date Record Pay
$1.0963 A Regular Feb 25, 2026 Jul 14, 2026 Jul 14, 2026 Jul 15, 2026
$1.0930 A Regular N/A Jul 13, 2026 Jul 14, 2026 Jul 15, 2026
$1.0864 A Regular Feb 25, 2025 Jul 15, 2025 Jul 15, 2025 Jul 16, 2025
$1.1934 A Regular Feb 27, 2024 Jul 08, 2024 Jul 09, 2024 Jul 10, 2024
$1.4126 A Regular N/A Jul 03, 2023 Jul 04, 2023 Jul 05, 2023
$0.9799 A Regular N/A Jul 05, 2022 Jul 06, 2022 Jul 07, 2022
$0.4342 S Regular N/A Jul 06, 2021 Jul 06, 2021 Jul 07, 2021
$0.4468 A Regular N/A Jul 05, 2021 Jul 06, 2021 Jul 07, 2021
$0.1684 A Regular N/A Nov 17, 2020 Nov 18, 2020 Nov 19, 2020
$0.0730 A Regular N/A Jul 02, 2019 Jul 03, 2019 Jul 04, 2019
$0.1139 A Regular N/A Jul 03, 2018 Jul 04, 2018 Jul 05, 2018
$0.1685 A Regular N/A Jul 03, 2017 Jul 04, 2017 Jul 05, 2017

Peer Comparison

Selected Drug Manufacturers - Specialty & Generic dividend payers we cover, strongest DividendRank first — for context, not a recommendation.

TickerNameYield5-Yr GrowthStreakRank
SGIOF Shionogi & Co., Ltd. 2.82% 6.0% 3 yrs 78
LVZPF Livzon Pharmaceutical Group Inc. 6.91% 15.8% 1 yr 73
NPNKF Nippon Shinyaku Co., Ltd. 3.34% -0.7% 0 yrs 72
RDY Dr. Reddy's Laboratories Limited 0.59% 6.5% 0 yrs 68

Related Guides & Lists

LABFF dividend — frequently asked questions

Does Laboratorios Farmaceuticos Rovi, S.A. pay a dividend?

Yes. Laboratorios Farmaceuticos Rovi, S.A. (LABFF) currently pays a dividend. The annualized dividend is about $1.10 per share, a yield of approximately 1.63%.

What is Laboratorios Farmaceuticos Rovi, S.A.'s dividend yield?

Laboratorios Farmaceuticos Rovi, S.A.'s dividend yield is approximately 1.63%, based on the most recent regular payment annualized against the current share price. Yields move as the share price changes.

How often does Laboratorios Farmaceuticos Rovi, S.A. pay dividends?

Laboratorios Farmaceuticos Rovi, S.A. pays dividends annually — 1 time per year.

How long has Laboratorios Farmaceuticos Rovi, S.A. paid dividends?

Laboratorios Farmaceuticos Rovi, S.A. has 9 years of dividend payments on record.

Data updated Oct 29, 2026. This research page is generated from Dividendly's structured market and dividend dataset using the approach described on our methodology and data sources pages. Data is automatically validated using defined rules and may also be periodically reviewed. Research only, not investment advice. Spotted a data error? Report it.